Nicolò Lauciello

Dr. Nicolò Lauciello

CNR-IBFM, Cefalù, Italy
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
Alessandro StefanoAlessandro Stefano
Alessandro Stefano
Fabiano BiniFabiano Bini
Fabiano Bini
EGEleonora Giovagnoli
Eleonora Giovagnoli
MDMariangela Dimarco
Mariangela Dimarco
Nicolò LaucielloNicolò Lauciello
Nicolò Lauciello
IDIldebrando D’angelo
Ildebrando D’angelo
Background: Breast cancer is the second leading cause of cancer-related mortality among women, accounting for 12% of cases. Early diagnosis, based on the identification of radiological features, such as masses and microcalcifications in mammograms, is crucial for reducing mortality rates. However, manual interpretation by radiologists is complex and subject to variability, emphasizing the need for automated diagnostic tools to enhance accuracy and efficiency. This study compares a radiomics workflow based on machine learning (ML) with a deep learning (DL) approach for classifying breast lesions as benign or malignant. Methods: matRadiomics was used to extract radiomics features from mammographic images of 1219 patients from the CBIS-DDSM public database, including 581 cases of microcalcifications and 638 of masses. Among the ML models, a linear discriminant analysis (LDA) demonstrated the best performance for both lesion types. External validation was conducted on a private dataset of 222 images to evaluate generalizability to an independent cohort. Additionally, a deep learning approach based on the EfficientNetB6 model was employed for comparison. Results: The LDA model achieved a mean validation AUC of 68.28% for microcalcifications and 61.53% for masses. In the external validation, AUC values of 66.9% and 61.5% were obtained, respectively. In contrast, the EfficientNetB6 model demonstrated superior performance, achieving an AUC of 81.52% for microcalcifications and 76.24% for masses, highlighting the potential of DL for improved diagnostic accuracy. Conclusions: This study underscores the limitations of ML-based radiomics in breast cancer diagnosis. Deep learning proves to be a more effective approach, offering enhanced accuracy and supporting clinicians in improving patient management.

4 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Alessandro StefanoAlessandro Stefano
Alessandro Stefano
Fabiano BiniFabiano Bini
Fabiano Bini
EGEleonora Giovagnoli
Eleonora Giovagnoli
MDMariangela Dimarco
Mariangela Dimarco
Nicolò LaucielloNicolò Lauciello
Nicolò Lauciello
IDIldebrando D'Angelo
Ildebrando D'Angelo
Background: Breast cancer is the second leading cause of cancer-related mortality among women, accounting for 12% of cases. Early diagnosis, based on the identifica-tion of radiological features such as masses and microcalcifications in mammograms, is crucial for reducing mortality rates. However, manual interpretation by radiologists is complex and subject to variability, emphasizing the need for automated diagnostic tools to enhance accuracy and efficiency. This study compares a radiomics workflow based on machine learning (ML) with a deep learning (DL) approach for classifying breast lesions as benign or malignant. Methods: matRadiomics was used to extract ra-diomics features from mammographic images of 1,219 patients from the CBIS-DDSM public database, including 581 cases of microcalcifications and 638 of masses. Among the ML models, linear discriminant analysis (LDA) demonstrated the best performance for both lesion types. External validation was conducted on a private dataset of 222 images to evaluate generalizability to an independent cohort. Additionally, a deep learning approach based on the EfficientNetB6 model was employed for comparison. Results: The LDA model achieved a mean validation AUC of 68.28% for microcalcifica-tions and 61.53% for masses. In external validation, AUC values of 66.9% and 61.5% were obtained, respectively. In contrast, the EfficientNetB6 model demonstrated supe-rior performance, achieving an AUC of 81.52% for microcalcifications and 76.24% for masses, highlighting the potential of DL for improved diagnostic accuracy. Conclu-sions: This study underscores the limitations of ML-based radiomics in breast cancer diagnosis. Deep learning proves to be a more effective approach, offering enhanced accuracy and supporting clinicians in improving patient management.

23 March 2026 in Clinical and Translational Imaging
Verified
Journal Article
Open access
PDF file
Nicolò LaucielloNicolò Lauciello
Nicolò Lauciello
Giorgio RussoGiorgio Russo
Giorgio Russo
Alessandro StefanoAlessandro Stefano
Alessandro Stefano
Radiomics is reshaping quantitative imaging by converting biomedical images into high-dimensional biomarkers that capture biological, molecular, and functional processes. While its clinical adoption—particularly in oncology—has accelerated, preclinical applications are rapidly expanding, driven by high-resolution imaging technologies and the need for robust quantitative frameworks to support translational research. Preclinical imaging spans micro-computed tomography (micro-CT), high-field magnetic resonance imaging (MRI), micro-positron emission tomography (micro-PET), micro-single-photon emission computed tomography (SPECT), and emerging modalities such as optical and photoacoustic imaging, applied across diverse experimental models from murine systems and patient-derived xenografts (PDX) to zebrafish and 3D cellular platforms. Despite its promise, preclinical radiomics faces challenges including variability in acquisition and reconstruction, limited sample sizes, lack of standardized workflows, and difficulties in biological interpretation. This review provides a systematic overview of current literature, organized by imaging modality and biological model, highlighting methodological patterns, shared limitations, and emerging opportunities. Special attention is given to harmonization strategies, publicly available datasets, and integrated software platforms that enable reproducible pipelines and lower technical barriers. Ultimately, this work delineates key directions to enhance reproducibility and accelerate the translation of preclinical radiomics into clinically meaningful applications.



29 May 2026 in Journal of Imaging
Verified
Journal Article
Open access
PDF file
Nicolò LaucielloNicolò Lauciello
Nicolò Lauciello
Giorgio RussoGiorgio Russo
Giorgio Russo
Alessandro StefanoAlessandro Stefano
Alessandro Stefano
Quantitative preclinical imaging enables non-invasive characterization of physiological, molecular, and functional processes providing measurable biomarkers for longitudinal and translational studies. This review systematically analyzes 60 studies published between 2015 and 2025, covering major imaging modalities including Positron emission tomography (PET), Single-Photon Emission Computed Tomography (SPECT), Magnetic resonance imaging (MRI), Computed Tomography (CT), optical imaging, and hybrid systems across murine and zebrafish models. We examine methodological frameworks for parameter extraction, reproducibility, and validation against biological reference standards, evaluating each modality through a cross-cutting analytical framework that distinguishes technical, biological, and computational sources of quantitative variance and identifies the current metrological maturity of harmonization infrastructure across platforms. Key comparative findings indicate that variability sources can be broadly categorized into technical (instrumentation, reconstruction, calibration) and biological (physiological heterogeneity, model-specific factors), with their interaction governing overall measurement uncertainty. Emerging computational approaches, including parametric modeling and artificial intelligence–assisted pipelines, show potential in reducing variance and improving parameter stability, although they introduce additional dependencies requiring validation. Collectively, this review frames quantitative preclinical imaging as a metrological discipline, emphasizing that reproducibility, bias control, and cross-modality harmonization are critical for generating robust and translationally relevant imaging biomarkers.